作者
Aline Houessinon, Albane Gicquel, Flora Bochereau, Christophe Louandre, Rémy Nyga, Corinne Godin, James Degonville, Emma Fournier, Zuzana Saidak, Claire Drullion, Jean-Claude Barbare, Bruno Chauffert, Catherine François, Olivier Pluquet, Antoine Galmiche
发表日期
2016/1/28
期刊
Cancer letters
卷号
370
期号
2
页码范围
242-249
出版商
Elsevier
简介
Sorafenib is the treatment of reference for advanced hepatocellular carcinoma (HCC). A decrease in the serum levels of Alpha-fetoprotein (AFP) is reported to be the biological parameter that is best associated with disease control by sorafenib. In order to provide a biological rationale for the variations of AFP, we analyzed the various steps of AFP production in human HCC cell lines exposed to sorafenib. Sorafenib dramatically reduced the levels of AFP produced by HCC cells independently of its effect on cell viability. The mRNA levels of AFP decreased upon sorafenib treatment, while the AFP protein remained localized in the Golgi apparatus. Sorafenib activated the Regulated Inositol-Requiring Enzyme-1α (IRE-1α) and the PKR-like ER Kinase (PERK)-dependent arms of the Unfolded Protein Response (UPR). The inhibition of IRE-1α partially restored the mRNA levels of AFP upon treatment with sorafenib. The …
引用总数
2016201720182019202020212022202347331341